Pfizer raises 2019 forecast as sales of cancer drug, heart medicine surge

Topics Pfizer | cancer drugs

Pfizer Inc reported a higher-than-expected third-quarter profit on Tuesday on increased sales of cancer drug Ibrance and a strong launch of new heart medicine Vyndaqel, prompting the largest U.S. drugmaker to lift its earnings forecast for the year. Pfizer raised its 2019 adjusted earnings forecast to $2.94 to $3.00 per share from its prior estimate of $2.

76 to $2.86, and its shares rose 3.6%. Analysts on average were expecting $2.82, according to Refinitiv IBES.   Pfizer Chief Executive Albert Bourla, on a conference call,.

This article is no longer available in our repository.

There could be multiple reasons for this.